{"id":27869,"date":"2023-03-23T09:47:53","date_gmt":"2023-03-23T09:47:53","guid":{"rendered":"https:\/\/cannabishealthnews.co.uk\/?p=27869"},"modified":"2023-03-23T10:10:58","modified_gmt":"2023-03-23T10:10:58","slug":"cannabis-improves-quality-of-life-in-patients-with-chronic-conditions","status":"publish","type":"post","link":"https:\/\/cannabishealthnews.co.uk\/2023\/03\/23\/cannabis-improves-quality-of-life-in-patients-with-chronic-conditions\/","title":{"rendered":"Cannabis improves quality of life in UK patients with chronic conditions"},"content":{"rendered":"
Real-world <\/span>analysis <\/span><\/a>of over 2,500 patients enrolled on the UK Medical Cannabis Registry, <\/a>which is run by Sapphire Medical Clinics, explores the effects of prescription cannabis on a broad range of chronic conditions.<\/span><\/p>\r\n As the number of medicinal cannabis patients continues to rise in the UK, with somewhere between 25,000 – 30,000 people now thought to have a legal prescription<\/a>, the new study highlights that just over 50% of patients are being prescribed the medication for chronic pain, whilst a quarter of patients receive the therapy for mental health conditions.<\/span><\/p>\r\n Data was collected from patients attending Sapphire Clinics between December 2019- February 2022, who completed follow up questionnaires at one, three, six and 12 months after treatment.<\/span><\/p>\r\n In total, 2,833 patients were included in the analysis, 43% were female and 57% male, with an average age of 42.<\/span><\/p>\r\n There were 31 different diagnoses recorded. Chronic non-cancer pain<\/a> was the most common indication prescribed for, reported by 32% of patients. This was followed by anxiety,<\/a> for which 11% of patients were prescribed cannabis.<\/span><\/p>\r\n Other pain-related chronic conditions were among the top 10 most common, including fibromyalgia (11%), neuropathic pain (8%), migraine (3%) and Ehlers-danlos syndrome (3%).<\/span><\/p>\r\n Around 11% of patients were prescribed cannabis for post traumatic stress disorder (PTSD)<\/a>, and depression, with around 6% receiving a prescription for the neurodivergent conditions, autism spectrum disorder (ASD) and ADHD.<\/a><\/span><\/p>\r\nA picture of cannabis patients in the UK<\/b><\/h4>\r\n